Now there’s a questionnaire to assess cancer patients’ “financial toxicity,” or potential difficulty paying for care, so that it can be factored into patient-physician dialogue and medical decision-making.
Pharmas are increasingly using the sort of mass-market consumer advertising once reserved for PPIs, allergy meds and ED drugs to raise awareness of specialty treatments and the rare(er) diseases that they treat. That’s a reflection both of where product portfolios are and of the value of getting even a small number of new starts on these high-priced medications.
The governor of Vermont blasted Movantik-makers AstraZeneca and Daiichi Sankyo for airing a condition awareness TV ad about opioid-induced constipation during the Super Bowl. The Northeast has been particularly hard-hit by the recent opioid abuse epidemic, and many a politician has found pharma-bashing a crowd-pleasing move.
AbbVie’s Androgel testosterone therapy got a boost from a major clinical trial which found the treatment effective at improving sexual function in older men. The Testosterone Trial found minimal impact on energy and mobility, but did improve mood and depression rates among study subjects.
There’s a lot of exciting stuff happening in sleep tracking and promotion technology. There’s also, of course, a lot of the sort of snake oil that attends any buzzy wellness problem, and The New Yorker has a fine time cataloguing all of it.